Stock Track | Moderna Stock Plummets 10% as Company Slashes 2025 Sales Forecast and Announces Job Cuts

Stock Track
Aug 01

Moderna, Inc. (MRNA) shares plummeted 10.10% in intraday trading on Friday following the release of its second-quarter 2025 financial results and a series of announcements that raised concerns about the company's near-term prospects. The biotechnology giant, known for its mRNA technology and COVID-19 vaccine, reported figures that beat analyst expectations but simultaneously delivered news that rattled investors.

While Moderna reported Q2 revenue of $142 million, surpassing the analyst consensus estimate of $112.9 million, and posted a smaller-than-expected loss of $2.13 per share compared to the anticipated $2.97 loss, the company's forward-looking statements overshadowed these positive results. Moderna lowered its 2025 revenue forecast to a range of $1.5 billion to $2.2 billion, cutting $300 million from the previous high-end projection. This reduction reflects ongoing challenges in the post-pandemic vaccine market and heightened uncertainty about future demand.

Adding to investor concerns, Moderna announced plans to reduce its global workforce by approximately 10% by the end of the year, shrinking to under 5,000 employees. This move, part of the company's efforts to trim operating expenses, signals a strategic shift as Moderna navigates a rapidly evolving healthcare landscape. The company aims to cut operating costs by $400 million in 2025, bringing them down to $5.9 billion to $6.1 billion. Despite these cost-saving measures, the market's focus remains on the top-line pressures facing the company as it transitions from its pandemic-era success to a more challenging business environment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10